Analysis

Drug Costs Threaten FDA Quick Approval Program, Docs Say

Law360, New York (July 17, 2017, 9:01 PM EDT) -- Drugs approved through the U.S. Food and Drug Administration's accelerated pathway often carry a high price tag, which at times leads insurers to refuse coverage of the drugs and may endanger the future of the process, researchers said in a New England Journal of Medicine policy analysis.

University of Pittsburgh School of Medicine professor Walid Gellad and Harvard Medical School professor and lawyer Aaron Kesselheim contend in the article that drug costs limit patient access. Private insurers can refuse to cover the drugs, keeping them away from patients in need, and government insurers have to shell out large sums for few...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS